Matica BioLabs is a specialized CDMO (Contract Development and Manufacturing Organization) dedicated to the development and production of advanced therapeutics, such as cell and gene therapies.
Utilizing cutting-edge production technologies and top-tier expertise that complies with global regulatory standards, we provide comprehensive development and manufacturing solutions tailored to our clients' unique requirements. Our strong process development and commercial-scale production capabilities facilitate the rapid development, production, and market introduction of biopharmaceutical products, creating dependable and efficient pathways for successful commercialization.

In compliance with Korea's laws on advanced regenerative medicine and biopharmaceutical safety, companies in the CDMO (Contract Development and Manufacturing Organization) space must secure specific regulatory permits to operate. In December 2020, Matica BioLabs became the first company in Korea to receive the "Advanced Biopharmaceutical Manufacturing" permit. Following this, Matica also secured the "Human Cell Management" and "Cell Processing Facility" permits, making it the first in the country to obtain all three key authorizations. These permits enable Matica BioLabs to handle a comprehensive range of human cells, including blood, fat, placenta, and umbilical cord.

These approvals have positioned Matica BioLabs to fast-track its CDMO business, leveraging CHA Biotech’s industry-leading expertise in stem cell and immune cell technology.

Securing all three permits provides a strong competitive advantage, as they are crucial for clients when selecting a CDMO partner. As the law requires, Matica’s adherence to strict Good Manufacturing Practice (GMP) standards ensures the production of high-quality advanced biopharmaceuticals. This solidifies Matica BioLabs as a trusted leader in the global cell and gene therapy production landscape.